Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture

被引:233
作者
Wang, Y
Huso, DL
Harrington, J
Kellner, J
Jeong, DK
Turney, J
McNiece, IK
机构
[1] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Div Hematol Malignancies, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, Dept Comparat Med, Baltimore, MD 21231 USA
[3] Cheju Natl Univ, Coll Appl Life Sci, Dept Anim Sci & Biotechnol, Cheju, South Korea
关键词
karyotype; mesenchymal stem cell; NOD/SCID mice; telomerase; transformation;
D O I
10.1080/14653240500363216
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background Human mesenchymal stem cells (hMSC) have been isolated and characterized extensively for a variety of clinical applications. Yet it is unclear how the phenomenon of hMSC plasticity can be safely and reasonably exploited for therapeutic use. Methods We have generated mesenchymal stem cells (MSC) from normal human BM and identified a novel cell population with a transformed phenotype. This cell population was characterized by morphologic, immunophenotypic, cytogenetic analyzes and telomerase expression. Its tumorigenicity in NOD/SCID mice was also studied. Results A subpopulation of cells in hMSC culture was noted to appear morphologically distinct from typical MSC. The cells were spherical, cuboidal to short spindle in shape, adherent and exhibited contact independent growth. Phenotypically the cells were CD133(+), CD34(-), CD45(-), CD90(low), CD105(-), VEGFR2(+). Cytogenetic analysis showed chromosome aneuploidy and translocations. These cells also showed a high level of telemerase activity compared with typical MSC. Upon transplantation into NOD/SCID mice, multiple macroscopic solid tumors formed in multiple organs or tissues. Histologically, these tumors were very poorly differentiated and showed aggressive growth with large areas of necrosis. Discussion The possible explanations for the origin of this cell population are: (1) the cells represent a transformed population of MSC that developed in culture; (2) abnormal cells existed in the donor BM at rare frequency and subsequently expanded in culture. In either case, the MSC culture may provide a suitable environment for transformed cells to expand or propagate in vitro. In summary, our data demonstrate the potential of transformed cells in hMSC culture and highlight the need for karyotyping as a release criteria for clinical use of MSC.
引用
收藏
页码:509 / 519
页数:11
相关论文
共 24 条
[1]  
Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO
[2]  
2-F
[3]   Mesenchymal stem cells: building blocks for molecular medicine in the 21st century [J].
Caplan, AI ;
Bruder, SP .
TRENDS IN MOLECULAR MEDICINE, 2001, 7 (06) :259-264
[4]   Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer [J].
Florek, M ;
Haase, M ;
Marzesco, AM ;
Freund, D ;
Ehninger, G ;
Huttner, WB ;
Corbeil, D .
CELL AND TISSUE RESEARCH, 2005, 319 (01) :15-26
[5]  
Gehling UM, 2000, BLOOD, V95, P3106
[6]   Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone [J].
Horwitz, EM ;
Gordon, PL ;
Koo, WKK ;
Marx, JC ;
Neel, MD ;
McNall, RY ;
Muul, L ;
Hofmann, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (13) :8932-8937
[7]   Gastric cancer originating from bone marrow-derived cells [J].
Houghton, J ;
Stoicov, C ;
Nomura, S ;
Rogers, AB ;
Carlson, J ;
Li, HC ;
Cai, X ;
Fox, JG ;
Goldenring, JR ;
Wang, TC .
SCIENCE, 2004, 306 (5701) :1568-1571
[8]   Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation [J].
Kim, DW ;
Chung, YJ ;
Kim, TG ;
Kim, YL ;
Oh, IH .
BLOOD, 2004, 103 (05) :1941-1948
[9]   Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH) [J].
Koç, ON ;
Day, J ;
Nieder, M ;
Gerson, SL ;
Lazarus, HM ;
Krivit, W .
BONE MARROW TRANSPLANTATION, 2002, 30 (04) :215-222
[10]   Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells [J].
Le Blanc, K ;
Rasmusson, I ;
Sundberg, B ;
Götherström, C ;
Hassan, M ;
Uzunel, M ;
Ringdén, O .
LANCET, 2004, 363 (9419) :1439-1441